Ignite Creation Date:
2025-12-26 @ 5:18 PM
Ignite Modification Date:
2026-03-01 @ 9:33 AM
Study NCT ID:
NCT02983006
Status:
COMPLETED
Last Update Posted:
2021-10-18
First Post:
2016-12-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
Sponsor:
NYU Langone Health
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Melanoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | TRAIL-DR5 | View |
| None | DS-8273a | View |
| None | Immunoglobulin gamma-1 (IgG1) | View |
| None | Cell mediated cytotoxicity (ADCC) | View |
| None | Complement dependent cytotoxicity (CDC) | View |
| None | DR5 | View |
| None | Immunoglobulin G4 (IgG4) | View |
| None | Monoclonal antibody | View |
| None | Programmed Cell Death 1 (PD-1) | View |